Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer

Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer This cohort study evaluates the association of early trastuzumab interruption with clinical outcomes in patients with ERBB2-positive breast cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer

Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/early-trastuzumab-interruption-and-recurrence-free-survival-in-erbb2-0vDV73AEhL

References (7)

  • D. Leong, T. Cosman, Muhammad Al-Hussein, Nidhi Tyagi, S. Karampatos, C. Barron, D. Wright, V. Tandon, P. Magloire, P. Joseph, D. Conen, P. Devereaux, P. Ellis, S. Mukherjee, S. Dhesy-Thind (2019)

    Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity

    JACC: CardioOncology, 1

  • X. Pivot, G. Romieu, M. Debled, J. Pierga, P. Kerbrat, T. Bachelot, A. Lortholary, M. Espié, P. Fumoleau, D. Serin, J. Jacquin, C. Jouannaud, M. Rios, S. Abadie-Lacourtoisie, L. Venat-Bouvet, L. Cany, S. Catala, David Khayat, L. Gambotti, I. Pauporté, C. Faure-Mercier, S. Paget‐Bailly, J. Henriques, J. Grouin, C. Piprot, L. Cals, L. Chaigneau, F. Demarchi, T. N'guyen, U. Stein, C. Villanueva, J. Breau, A.K. Chouahnia, P. Saintigny, F. Boué, P. deSaint-Hilaire, I. Guimont, N. Grossat, B. Valenza, E. Levy, J. Medioni, C. Delbaldo, J. Grenier, D. Pouessel, S. Lavau-Denès, C. Falandry, C. Fournel-Federico, G. Freyer, S. Tartas, V. Trillet-Lenoir, F. Bons, G. Auclerc, S. Chièze, N. Raban, C. Tournigand, S. Trager-Maury, G. Bousquet, C. Cuvier, S. Giacchetti, A. Hocini, C. Lemaignan, J. Misset, D. Avenin, C. Beerblock, J. Gligorov, P. Rivera, H. Roché, P. Bougnoux, N. Hajjaji, O. Capitain, R. Delva, P. Maillart, P. Soulié, H. Bonnefoi, M. Durand, N. Madranges, L. Mauriac, P. Chollet, A. Dillies, X. Durando, JP Ferrière, C. Mouret-Reynier, JM Nabholtz, I. Praagh, P. Cottu, V. Diéras, A. Durieux, M. Galotte, V. Girre, S. Henry, I. Iurisci, M. Jouve, V. Laurence, L. Mignot, S. Piperno-Neumann, P. Tresca, B. Coudert, E. Ferrant, F. Mayer, A. Vanneuville, J. Bonneterre, V. Servent, L. Vanlemmens, P. Vennin, J. Guastalla, P. Biron, L. Dupuy-Brousseau, L. Lancry, I. Ray-Coquard, P. Rebattu, O. Trédan, JM Extra, F. Rousseau, C. Tarpin, M. Fabbro, É. Luporsi, L. Uwer, B. Weber, D. Berton-Rigaud, E. Bourbouloux, M. Campone, J. Ferrero, P. Follana, R. Largillier, V. Mari, B. Costa, H. Curé, J. Eymard, N. Jovenin, D. Lebrun, J. Meunier, G. Yazbek, D. Gedoin, B. Laguerre, C. Lefeuvre, E. Vauléon, A. Chevrier, C. Guillemet, M. Leheurteur, O. Rigal, I. Tennevet, C. Veyret, E. Brain, M. Guiterrez, F. Mefti-Lacheraf, T. Petit, F. Dalenc, L. Gladieff, F. Andre, S. Delaloge, J. Dômont, J. Ezenfis, M. Spielmann, P. Guillet, V. Boulanger, J. Provençal, L. Stefani, C. Alliot, D. Ré, C. Bellaiche-Miccio, G. Boutan-Laroze, R. Vanica, P. Dion, G. Sadki-Benaoudia, A. Marti, AL Villing, B. Slama, JL Dutel, S. Nguyen, R. Saad, O. Arsene, Z. Merad-Boudia, H. Orfeuvre, J. Egreteau, MJ Goudier, R. Lamy, B. Leduc, C. Sarda, B. Salles, C. Agostini, I. Cauvin, A. Dufresne, M. Mangold, S. Lebouvier-Sadot, B. Audhuy, J. Barats, S. Cluet-Dennetiere, D. Zylberait, G. Netter, L. Gautier-Felizot, I. Cojean-Zelek, A. Plantade, S. Vignot, E. Guardiola, P. Marti, I. deHartingh, R. Diab, A. Dietmann, S. Ruck, C. Portois, S. Oddou-Lagranière, F. Campos-Gazeau, A. Bourcier, F. Priou, JF Geay, D. Mayeur, P. Gabez, R. Elamarti, M. Combe, P. Raichon-Patru, P. Amsalhem, J. Dauba, D. Paraiso, F. Guinet, B. Duvert, M. Litor, F. Kara-Slimane, A. Bichoffe, N. Denizon, P. Soyer, F. Morvan, S. Van-Hulst, L. Vincent, C. Alleaume, P. Ibáñez-Martín, A. Youssef, Z. Tadrist, E. Carola, C. Pourny, JF Toccanier, N. Al-Aukla, K. Mahour-Bacha, J. Salvat, P. Nouyrigat, S. Clippe, M Gouttebel, L. Vedrine, G. Clavreul, O. Collard, D. Mille, Y. Goubely, R. Hervé, S. Kirscher, F. Plat, V. Delecroix, V. Ligeza-Poisson, D. Coeffic, D. Fric, C. Garnier, C. Leyronnas, T. Kreitman, E. Teissier, P Martin, S. deCordoue, C. Elkouri, JF Ramée, C. Laporte, O. Bernard, T. Altwegg, A. Darut‐Jouve, JP Dujols, F. Darloy, C. Giraud, V. Pottier-Kyndt, N. Achour, S. Drony, M. Moriceau, C. Sarrazin, JC Legueul, J. Mandet, D. Besson, A. Hardy-Bessard, J. Cretin, P. Houyau, E. Achille, D. Genet, H. Thévenot, A. Moran-Ribon, JM Pavlovitch, P. Ardisson, I. Moullet, B. Couderc, V. Fichet, F. Burki, A. Auliard, C. Levache, P. Cailleux, F. Schaeffer, N. Albin, D. Sevin-Robiche, J. Domas, S. Ellis, P. Montcuquet, GA Baumont, M. Begue, S. Greget, J. Ratoanina, A. Vanoli, C. Bielsa, M. Bonichon-Lamichhane, D. Jaubert, H. Laharie-Mineur, L. Alcaraz, E. Legouffe, H. Bourgeois, G. Cartron, F. Denis, O. Dupuis, G. Ganem, S. Roche-Forestier, L. Delzenne, E. Chirat, J. Baticle, E. Beguier, S. Jacquot, E. Janssen, H. Lauche, A. Lerol, JP Chantelard, G. L'helgoualc'h, E. Antoine, A. Kanoui, JF Llory, J.-M. Vannetzel, J. Vignoud, C. Bruna, T. Facchini, K. Moutel-Corviole, A. Voloch, A. Ghoul, D. Loiseau, N. Barbet, N. Dohollou, K. Yakendji (2019)

    6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

    The Lancet, 393

  • Leong (2019)

    Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial.

    JACC: Cardiooncology, 1

  • F. Lynce, A. Barac, X. Geng, C. Dang, A. Yu, A. Yu, K. Smith, C. Gallagher, P. Pohlmann, R. Nunes, R. Nunes, P. Herbolsheimer, R. Warren, M. Srichai, M. Hofmeyer, A. Cunningham, P. Timothee, F. Asch, Ayesha Shajahan-Haq, M. Tan, C. Isaacs, S. Swain (2019)

    Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

    Breast Cancer Research and Treatment, 175

  • A. Yu, N. Yadav, Betty Lung, A. Eaton, H. Thaler, C. Hudis, C. Dang, R. Steingart (2014)

    Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer

    Breast Cancer Research and Treatment, 149

  • D. Slamon, W. Eiermann, N. Robert, T. Pieńkowski, Miguel Martín, M. Press, J. Mackey, J. Glaspy, A. Chan, M. Pawlicki, T. Pintér, V. Valero, Mei-Ching Liu, G. Sauter, G. Minckwitz, F. Visco, V. Bée, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M. Lindsay, A. Riva, J. Crown (2011)

    Adjuvant trastuzumab in HER2-positive breast cancer.

    The New England journal of medicine, 365 14

  • H. Earl, L. Hiller, A. Vallier, S. Loi, K. McAdam, L. Hughes-Davies, A. Harnett, M. Ah-See, R. Simcock, D. Rea, S. Raj, P. Woodings, M. Harries, Donna Howe, K. Raynes, Helen Higgins, M. Wilcox, C. Plummer, J. Mansi, I. Gounaris, B. Mahler-Araujo, E. Provenzano, A. Chhabra, J. Abraham, C. Caldas, P. Hall, C. McCabe, C. Hulme, D. Miles, A. Wardley, D. Cameron, J. Dunn, R. Agarwal, H. Algurafi, R. Allerton, C. Archer, A. Armstrong, C. Bale, L. Barraclough, U. Barthakur, C. Bedi, K. Benstead, D. Bloomfield, R. Bowen, C. Bradley, Janet Brown, M. Butt, M. Churn, S. Cleator, J. Cliff, P. Crellin, M. Daly, Shiroma Silva-Minor, A. Dhadda, Omar Din, S. Down, H. Earl, D. Eaton, A. Eichholz, D. Epurescu, Chee Goh, A. Goodman, R. Grieve, M. Hadaki, C. Harper-wynne, M. Harries, L. Hayward, A. Humphreys, H. Innes, M. Jafri, A. Jegannathen, M. Kelleher, H. Kristeleit, Daniela Lee, S. Lupton, C. MacGregor, Z. Malik, J. Mansi, J. Marshall, K. McAdam, Trevor McGolick, R. Mehra, D. Miles, N. Mithal, C. Moss, A. Moss, M. Mukesh, A. Neal, D. Nelmes, H. Neville-Webbe, J. Newby, S. O'Reilly, P. Ostler, M. Persic, L. Pettit, S. Raj, F. Raja, D. Rea, C. Reed, A. Rigg, H. Roe, Nihal Shah, P. Simmonds, E. Sims, Sarah Smith, N. Storey, W. Taylor, N. Thanvi, K. Tipples, J. Vaidya, M. Varughese, Anup Vinayan, N. Walji, S. Waters, P. Woodings, Kathryne Wright, S. Yahya (2019)

    6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

    Lancet (London, England), 393

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.4749
Publisher site
See Article on Publisher Site

Abstract

This cohort study evaluates the association of early trastuzumab interruption with clinical outcomes in patients with ERBB2-positive breast cancer.

Journal

JAMA Oncology – American Medical Association

Published: Dec 15, 2020

There are no references for this article.